The rationality of combining second-generation antiandrogens with 177Lu-PSMA or its alpha-emitting congeners for better and durable results
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Radiology Nuclear Medicine and imaging,General Medicine
Reference8 articles.
1. Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Parker;Ann Oncol,2015
2. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study;Hofman;Lancet Oncol,2018
3. 177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy;Baum;J Nucl Med,2016
4. Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen.;Kulkarni;Br J Radiol,2018
5. Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer;Li;Nature,2015
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. From Despair to Hope: First Arabic Experience of 177Lu-PSMA and 161Tb-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer;Cancers;2024-05-23
2. Combined 177 Lu‐PSMA‐617 PRLT and abiraterone acetate versus 177 Lu‐PSMA‐617 PRLT monotherapy in metastatic castration‐resistant prostate cancer: An observational study comparing the response and durability;The Prostate;2021-09
3. 177Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer;Biomedicines;2021-04-15
4. Concept proposal for a six-tier integrated dual tracer PET-CT (68Ga-PSMA and FDG) image scoring system (‘Pro-PET’ score) and examining its potential implications in metastatic castration-resistant prostate carcinoma theranostics and prognosis;Nuclear Medicine Communications;2021-02-05
5. Towards personalizing treatment strategies in mCRPC: can dual-tracer PET-CT provide insights into tumor biology, guide the optimal treatment sequence, and individualize decision-making (between chemotherapy, second-generation anti-androgens and PSMA-directed radioligand therapy) early in the disease course?;European Journal of Nuclear Medicine and Molecular Imaging;2019-11-27
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3